StockData
Virax Biolabs Group Ltd logo

Virax Biolabs Group Ltd (VRAX) stock

VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026Score 9/30
$0.45−0.00 (-0.65%)

Close on Nov 17, 2026Market cap $257.81KP/E –Yield –

Virax Biolabs operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

For fiscal 2026 it was -$4.62M. The highest annual figure on record is -$590.19K in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2026Mar 31, 2026-$4.62M–
FY2025Mar 31, 2025-$4.56M–
FY2024Mar 31, 2024-$6.40M–
FY2023Mar 31, 2023-$4.18M–
FY2022Mar 31, 2022-$809.07K–
FY2021Mar 31, 2021-$590.19K–

More Virax Biolabs figures

See a number that looks wrong?